Steno Diabetes Center, Gentofte Hospital, Denmark.
Diabet Med. 2010 Oct;27(10):1144-50. doi: 10.1111/j.1464-5491.2010.03083.x.
Our aim was to evaluate the markers of tubulointerstitial damage, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule1 (KIM1) in Type 1 diabetic patients with different levels of albuminuria and in control subjects. In addition, the effect of renoprotective treatment on urinary NGAL was evaluated in diabetic nephropathy.
This was a cross-sectional study in 58 normoalbuminuric (u-albumin <30 mg/24 h), 45 microalbuminuric (30-300 mg/24 h) and 45 macroalbuminuric (>300 mg/24 h) Type 1 diabetic patients and 55 non-diabetic control subjects. Furthermore, in a second study, urine-NGAL was measured in a randomized cross-over study of 56 Type 1 diabetic patients with diabetic nephropathy treated with lisinopril 20, 40 and 60 mg daily.
Urine-NGAL levels were [geometric mean (95% CI)]: control subjects 74 (52-104) (pg/mmol creatinine), normoalbuminuric 146 (97-221), microalbuminuric 222 (158-312) and macroalbuminuric group 261 (175-390). Urine-NGAL increased significantly from the normo- to the micro- and further to the macroalbuminuric group (P<0.05). Urine-NGAL was higher in normoalbuminuric vs. control subjects (P<0.01). Plasma-NGAL was significantly higher in the normoalbuminuric and macroalbuminuric groups than in the control group. Urine-KIM1 was higher in all diabetic groups than in the control group (P<0.001), with no difference between diabetic groups. During lisinopril treatment, urine-NGAL was reduced (95% CI) 17% (11-50) (not significant).
Urine-NGAL and urine-KIM1 (u-KIM1) are elevated in Type1 diabetic patients, with or without albuminuria, indicating tubular damage at an early stage. Urine-NGAL increases significantly with increasing albuminuria. The ACE inhibitor lisinopril reduced urine-NGAL, but this was not statistically significant.
我们的目的是评估不同白蛋白尿水平的 1 型糖尿病患者和对照组中肾小管间质损伤标志物中性粒细胞明胶酶相关脂质运载蛋白 (NGAL) 和肾损伤分子 1 (KIM1)。此外,还评估了在糖尿病肾病中,肾保护治疗对尿 NGAL 的影响。
这是一项横断面研究,纳入 58 例正常白蛋白尿(u-白蛋白<30 mg/24 h)、45 例微量白蛋白尿(30-300 mg/24 h)和 45 例大量白蛋白尿(>300 mg/24 h)的 1 型糖尿病患者和 55 名非糖尿病对照者。此外,在第二项研究中,对 56 例接受赖诺普利 20、40 和 60 mg 每日治疗的糖尿病肾病患者进行随机交叉研究,测量尿-NGAL。
尿-NGAL 水平[几何均数(95%CI)]:对照组为 74(52-104)(pg/mmol 肌酐),正常白蛋白尿组为 146(97-221),微量白蛋白尿组为 222(158-312),大量白蛋白尿组为 261(175-390)。尿-NGAL 从正常白蛋白尿组到微量白蛋白尿组再到大量白蛋白尿组显著升高(P<0.05)。与对照组相比,正常白蛋白尿组尿-NGAL 更高(P<0.01)。正常白蛋白尿组和大量白蛋白尿组的血浆-NGAL 均明显高于对照组。所有糖尿病组的尿-KIM1 均高于对照组(P<0.001),但糖尿病组之间无差异。在赖诺普利治疗期间,尿-NGAL 降低(95%CI)17%(11-50)(无统计学意义)。
1 型糖尿病患者,无论是否有白蛋白尿,尿-NGAL 和尿-KIM1(u-KIM1)均升高,表明早期肾小管损伤。尿-NGAL 随着白蛋白尿的增加而显著增加。血管紧张素转换酶抑制剂赖诺普利降低了尿-NGAL,但无统计学意义。